This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to investigate the mechanisms by which mechanical and hormonal signals are integrated within bone cells to stimulate bone formation. The total award amount is $175,948 and will be performed over 5 years from June 1, 2025 to May 31, 2030. The research aims to identify how the focal...
This $483,070 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 "Arthritis, Musculoskeletal and Skin Diseases Research" supports research into the dynamics of bone extracellular matrix (ECM) assembly and resorption. The study aims to investigate how osteogenic cellular dynamics, differentiation, and cell fate are integrated with collagen assembly and mineralization, as well as how osteoclast bone resorption...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to investigate the role of glutamine metabolism in regulating osteoclast differentiation and bone resorption. The $588,302 award, with a project period from February 1, 2025 to January 31, 2030, will be conducted by The University of Texas Southwestern Medical Center. The key...
This $313,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research by Emory University to establish phosphorylated WNT5A produced by osteoclasts as a potential anabolic bone drug. The research aims to determine how osteoclast-derived phospho-WNT5A can enhance bone formation in vivo and elucidate the cellular and molecular mechanisms by...
This federal Project Grant award, valued at $626,879.00, was awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research aims to explore a novel mouse model of large-scale bone regeneration to unravel the cellular and molecular mechanisms governing the initiation and coordination of bone repair following extensive injuries. Specifically, the research will...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846) will provide $1,469,862.00 to The Regents of the University of California, San Francisco over 5 years starting on Sep 5, 2024. The project aims to elucidate the biological and material mechanisms by which exercise controls bone quality, focusing on the role of osteocytes and their mitochondrial function. The research will leverage established mouse models to investigate how...
This Project Grant award, provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to resolve the mechanism of osteoclast multinucleation and signaling in bone remodeling. The $249,000 award to the Rector & Visitors of the University of Virginia will fund a 3-year research project to: 1) identify the domain of the lupus La protein that regulates osteoclast...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,037,340 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the Broad Institute, Inc. The grant aims to transform the Musculoskeletal Knowledge Portal (MSKKP) into an established biomedical knowledgebase that integrates curated 'omics datasets, processes them through analytical pipelines, and presents the results through web-based visualizations. The...
This Project Grant award of $623,628 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support the University of Vermont & State Agricultural College's research to investigate how human long non-coding RNAs (lncRNAs) epigenetically regulate human mesenchymal stem cell commitment and osteoblast lineage progression. The research aims to mechanistically define the...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $550,812 to the University of California, Los Angeles (UCLA) to investigate the role of the KDM5C gene on the X chromosome in contributing to sex differences in adipose tissue function and risk of cardiovascular disease. The key objectives are to: 1) Determine if KDM5C gene dosage impacts weight/fat gain in hypogonadal states; 2)...
This federal Project Grant award, valued at $1,938,605.00 and awarded on August 19, 2024 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), aims to define the mechanisms by which the X-linked chromatin modifying enzyme KDM5C regulates bone mass in females.
The primary objectives are to investigate how the loss of KDM5C affects osteoclast function, osteoclast-osteoblast communication, and osteoclast energy metabolism. The research team will also examine the epigenetic programming of osteoclast progenitors under KDM5C regulation, using genomic and epigenetic profiling analyses. Additionally, the project will assess the impact of KDM5C deletion and pharmacological inhibition on mouse models of osteoporosis induced by estrogen deficiency, inflammation, or aging.
This research falls under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), which supports comprehensive investigations into the causes, treatments, and prevention of arthritis, musculoskeletal, and skin diseases. The findings from this project are expected to contribute to a better understanding of the genetic factors and mechanisms that can be targeted to improve women's bone health.